While statins can slightly elevate the risk of new-onset diabetes mellitus, mainly by reducing sensitivity to blood sugar fluctuations via inhibiting islet β-cell glucose transporter-2 and insulin receptors in tissues, current clinical evidence suggests that PCSK9 monoclonal antibodies are sufficiently safe (McNamara et al., 2009; Gotoh and Negishi, 2015). This evidence concerns the gene PCSK9 and diabetes mellitus.